GC Biopharma Corp., provider of biopharmaceutical products in South Korea, has signed an asset purchase agreement with Catalyst Biosciences to acquire three programs related to the orphan hematology disorders. GC Biopharma will gain three programs, including “Marzeptacog alfa (MarzAA)”, an engineered factor VIIa which is ready for Phase 3 clinical development. In its previous clinical development trials, “MarzAA” demonstrated efficacy and safety as a treatment for r...